{
    "clinical_study": {
        "@rank": "102317", 
        "acronym": "BIBC", 
        "arm_group": {
            "arm_group_label": "bevacizumab combined neoadjuvant chemotherapy"
        }, 
        "brief_summary": {
            "textblock": "- The purpose of this study is to evaluate the efficacy and safety of the application of\n      bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer."
        }, 
        "brief_title": "Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Bevacizumab", 
            "Neoadjuvant Chemotherapy", 
            "Molecular Targeted Therapy"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HER2-negative breast cancer patients\n\n          -  Without surgery\n\n          -  Plans to neoadjuvant chemotherapy\n\n        Exclusion Criteria:\n\n          -  HER2-positive breast cancer patients\n\n          -  Post-operative patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Breast cancer patients of vascular endocrine surgery department in Xijing Hospital"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652560", 
            "org_study_id": "QTDS-01"
        }, 
        "intervention": {
            "arm_group_label": "bevacizumab combined neoadjuvant chemotherapy", 
            "description": "The patients will be treated with Avastin combined neoadjuvant chemotherapy", 
            "intervention_name": "bevacizumab", 
            "intervention_type": "Drug", 
            "other_name": "Avastin"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bevacizumab", 
            "neoadjuvant chemotherapy", 
            "HER2-negative breast cancer"
        ], 
        "lastchanged_date": "July 25, 2012", 
        "location": {
            "contact": {
                "email": "nanlin-74@163.com", 
                "last_name": "Nanlin Li, Ph.D", 
                "phone": "+86-186-2963-7041"
            }, 
            "contact_backup": {
                "email": "louch2008@126.com", 
                "last_name": "Hongyu Xiao, Master", 
                "phone": "+86-186-2963-7040"
            }, 
            "facility": {
                "address": {
                    "city": "Xi`an", 
                    "country": "China", 
                    "state": "Shaanxi", 
                    "zip": "710032"
                }, 
                "name": "Xijing Hospital \uff0c Fourth Military Medical University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy", 
        "overall_contact": {
            "email": "nanlin-74@163.com", 
            "last_name": "Nanlin Li, Phd", 
            "phone": "+86-186-2963-7041"
        }, 
        "overall_contact_backup": {
            "email": "louch2008@116.com", 
            "last_name": "Hongyu Xiao, Master", 
            "phone": "+86-186-2963-7040"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.", 
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "From enrollment to disease progression"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652560"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Xijing Hospital", 
            "investigator_full_name": "LiNanlin,Ph.D, Chief Physician,Clinical Professor", 
            "investigator_title": "The department of Vascular endocrine surgery", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.", 
            "measure": "overall response", 
            "safety_issue": "No", 
            "time_frame": "From enrollment to disease progression"
        }, 
        "source": "Xijing Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "LiNanlin,Ph.D, Chief Physician,Clinical Professor", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2012"
    }
}